3.0.0 3537 2022-02-08T23:15:31Z 2022-02-08T23:15:31Z Senate S 2020-03-19 116 ssfi00 Finance Committee Senate Standing Referred to 2020-03-19T18:25:31Z Protecting Our Pharmaceutical Supply Chain from China Act of 2020 116 6482 HR 2020-07-13 Referred to the Subcommittee on Oversight and Investigations. Identical bill CRS Protecting Our Pharmaceutical Supply Chain from China Act of 2020 116 3635 S 2020-05-06 Read twice and referred to the Committee on Finance. Related bill CRS 2020-03-19 ssfi00 Finance Committee Senate Read twice and referred to the Committee on Finance. IntroReferral 2020-03-19 Introduced in Senate IntroReferral 10000 9 Library of Congress C001095 Sen. Cotton, Tom [R-AR] Tom Cotton R AR N B001243 Sen. Blackburn, Marsha [R-TN] Marsha Blackburn R TN 2020-03-19 True C001098 Sen. Cruz, Ted [R-TX] Ted Cruz R TX 2020-03-19 True Health Asia Business expenses China Drug safety, medical device, and laboratory regulation Government information and archives Health care costs and insurance Health programs administration and funding Health technology, devices, supplies Income tax deductions Manufacturing Military medicine Military procurement, research, weapons development Prescription drugs Public contracts and procurement Trade restrictions Veterans' medical care Health 00 2020-03-19 Introduced in Senate 2021-09-08T19:43:59Z Protecting Our Pharmaceutical Supply Chain from China Act of 2020

This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing Chinese ingredients, requires drugs to be labeled for country of origin, and offers domestic manufacturing facility tax incentives.

]]> Protecting Our Pharmaceutical Supply Chain from China Act of 2020 Display Title Protecting Our Pharmaceutical Supply Chain from China Act of 2020 Short Title(s) as Introduced Protecting Our Pharmaceutical Supply Chain from China Act of 2020 Introduced in Senate IS Official Title as Introduced A bill to require the Secretary of Health and Human Services to maintain a list of the country of origin of all drugs marketed in the United States, to ban the use of Federal funds for the purchase of drugs manufactured in China, and for other purposes. Introduced in Senate IS Introduced in Senate 2020-03-19T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-116s3537is/xml/BILLS-116s3537is.xml 2020-03-19 Read twice and referred to the Committee on Finance. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.